2022 CVT-301 (Parkinson’s Disease) – Forecast and Market Analysis - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

2022 CVT-301 (Parkinson’s Disease) – Forecast and Market Analysis

Description:

Get a detailed report at . CVT-301 has been developed by Civitas Therapeutics as the company’s leading candidate for the treatment of OFF episodes in Parkinson’s disease. Using the ARCUS inhaler platform, levodopa is inhaled into the lung where it is delivered to the blood, avoiding the gastrointestinal tract and producing more rapid effects than orally administered levodopa. CVT-301 will be taken as needed, similar to a “rescue inhaler,” which is common in the asthma market. It will not replace the patient’s current oral doses of levodopa or other medications, but will be taken in addition to them. – PowerPoint PPT presentation

Number of Views:68

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: 2022 CVT-301 (Parkinson’s Disease) – Forecast and Market Analysis


1
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.
  • Published Mar 2014
  • Single User PDF US 3495
  • Corporate User PDF US 10485

2
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Parkinsons disease is a progressive condition
    that is characterized by bradykinesia, muscular
    rigidity, tremor, and postural instability. As
    the second most common neurodegenerative
    disorder, Parkinsons disease may affect
    individuals of any age but prevalence is
    increased with age and it is most common in the
    elderly. Dopaminergic therapies have been fairly
    effective in treating bradykinesia, but several
    unmet needs remain. Some needs will be met during
    the forecast period from 2012-2022, while others,
    such as the need for disease-modifying drugs,
    will remain.
  • Researcher expects that advancements will be made
    in levodopa administration and that four new
    molecular entities will be introduced to the
    market by 2022, these factors along with
    increased patient numbers from an aging
    population will drive the market during the
    forecast period.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • CVT-301 has been developed by Civitas
    Therapeutics as the companys leading candidate
    for the treatment of OFF episodes in Parkinsons
    disease. Using the ARCUS inhaler platform,
    levodopa is inhaled into the lung where it is
    delivered to the blood, avoiding the
    gastrointestinal tract and producing more rapid
    effects than orally administered levodopa.
  • CVT-301 will be taken as needed, similar to a
    rescue inhaler, which is common in the asthma
    market. It will not replace the patients current
    oral doses of levodopa or other medications, but
    will be taken in addition to them.
  • Inquire about this report at http//www.marketopti
    mizer.org/contacts/purchase?rname7294

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Scope
  • Overview of Parkinsons disease, including
    epidemiology, etiology, symptoms, diagnosis,
    pathology and treatment guidelines as well as an
    overview on the competitive landscape.
  • Detailed information on CVT-301 including product
    description, safety and efficacy profiles as well
    as a SWOT analysis.
  • Sales forecast for CVT-301 for the top six
    countries from 2012 to 2022.
  • Sales information covered for the US, France,
    Germany, Italy, Spain and the UK.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • Reasons to buy
  • Understand and capitalize by identifying products
    that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding
    the changing competitive landscape for
    Parkinsons disease
  • Effectively plan your MA and partnership
    strategies by identifying drugs with the most
    promising sales potential
  • Make more informed business decisions from
    insightful and in-depth analysis of CVT-301
    performance
  • Obtain sales forecast for CVT-301 from 2012-2022
    in the top six countries (the US, France,
    Germany, Italy, Spain and the UK).
  • Get a detailed report at http//www.marketoptimize
    r.org/cvt-301-parkinsons-disease-forecast-and-mark
    et-analysis-to-2022.html .

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
6
CVT-301 (Parkinsons Disease) Forecast and
Market Analysis to 2022
  • About Us
  • marketoptimizer.org is an online market research
    reports library of 250,000 in-depth studies of
    over 5000 micro markets. Our database includes
    reports by leading publishers from across the
    globe. We provide 24/7 online and offline support
    service to our customers. marketoptimizer.org
    also offers company data, country profiles,
    trends, information and analysis on the sector of
    your interest.
  • Visit Us _at_
  • http//www.marketoptimizer.org
  • Follow Us

Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org
About PowerShow.com